<DOC>
	<DOCNO>NCT00369161</DOCNO>
	<brief_summary>This study design evaluate whether tacrolimus dose reduction de novo renal recipient receive everolimus preserve renal function maintain efficacy .</brief_summary>
	<brief_title>A Twelve-month , Multicenter , Open-label , Randomized Study Safety , Tolerability Efficacy Everolimus With Basiliximab , Corticosteroids Two Different Exposure Levels Tacrolimus de Novo Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion Male female 1865 year old Patient receive primary kidney transplant cadaveric , live unrelated nonhuman leucocyte antigen ( HLA ) identical living relate donor Recipient kidney cold ischemia time ( CIT ) &lt; 30 hour Recipient kidney donor 1065 year old Patient able receive first dose tacrolimus within 24 hour graft reperfusion Female capable become pregnant must negative pregnancy test require practice medically approve method birth control duration study period three month follow discontinuation investigational drug Patient willing capable give write informed consent study participation able participate study 12 month Exclusion criterion Patient previously receive organ transplant Recipient multiple organ transplant Recipient kidney transplant non heartbeating donor Recipient donor specific transfusion Recipient ABO incompatible transplant Tcell crossmatch positive transplant Patient current Panel Reactive Antibodies ( PRA ) level ≥ 50 % Recipient kidney donor test positive hepatitis B surface antigen hepatitis C antibodies Patient human immunodeficiency virus ( HIV ) positive Patient positive hepatitis C serology hepatitis B surface antigen positive evidence liver injury indicate aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) level ≥2.5 time upper limit normal ( UNL ) . Viral serology result obtain within 6 month prior administration first dose Certican™ acceptable Patient severe hypercholesterolemia ( 350 mg/dL , 9.1 mmoL/dL ) hypertriglyceridemia ( 500 mg/dL , 5.6 mmoL/L ) Patient white blood cell ( WBC ) count 3,000/mm3 platelet count 75,000/mm3 Patient severe allergy require acute ( within 4 week baseline ) chronic treatment , hypersensitivity drug similar Certican ( e.g. , macrolides ) Patient treat immunosuppressive drug investigational drug within 4 week prior administration first dose Certican Patient uncontrolled infection Patient surgical medical condition , current transplant , opinion investigator , precludes enrollment trial Patient know malignancy history malignancy within last 5 year successfully treat localized basal squamous cell carcinoma skin Abnormal physical laboratory finding clinical significance within 2 week prior administration first dose Certican™ investigator 's discretion would interfere objective study Breast feed woman Patient symptom significant somatic mental illness unresolved history drug alcohol abuse Patient unable cooperate communicate investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>